Skip to main content
Top
Published in: Molecular Cancer 1/2018

Open Access 01-12-2018 | Letter to the Editor

Enhanced expression of histone chaperone APLF associate with breast cancer

Authors: Aditi Majumder, Khaja Moheiddin Syed, Ananda Mukherjee, Manendra Babu Lankadasari, Juberiya Mohammed Azeez, Sreeharshan Sreeja, Kuzhuvelil B. Harikumar, Madhavan Radhakrishna Pillai, Debasree Dutta

Published in: Molecular Cancer | Issue 1/2018

Login to get access

Abstract

DNA damage-specific histone chaperone Aprataxin PNK-like factor (APLF) regulates mesenchymal-to-epithelial transition (MET) during cellular reprogramming. We investigated the role of APLF in epithelial-to-mesenchymal transition (EMT) linked to breast cancer invasiveness and metastasis. Here, we show that a significant manifestation of APLF is present in tumor sections of patients with invasive ductal carcinoma when compared to their normal adjacent tissues. APLF was significantly induced in triple negative breast cancer (TNBC) cells, MDAMB-231, in comparison to invasive MCF7 or normal MCF10A breast cells and supported by studies on invasive breast carcinoma in The Cancer Genome Atlas (TCGA). Functionally, APLF downregulation inhibited proliferative capacity, altered cell cycle behavior, induced apoptosis and impaired DNA repair ability of MDAMB-231 cells. Reduction in APLF level impeded invasive, migratory, tumorigenic and metastatic potential of TNBC cells with loss in expression of genes associated with EMT while upregulation of MET-specific gene E-cadherin (CDH1). So, here we provided novel evidence for enrichment of APLF in breast tumors, which could regulate metastasis-associated EMT in invasive breast cancer. We anticipate that APLF could be exploited as a biomarker for breast tumors and additionally could be targeted in sensitizing cancer cells towards DNA damaging agents.
Appendix
Available only for authorised users
Literature
1.
go back to reference Syed KM, Joseph S, Mukherjee A, Majumder A, Teixeira JM, Dutta D, et al. Histone chaperone APLF regulates induction of pluripotency in murine fibroblasts. J Cell Sci. 2016;129:4576–91.PubMedPubMedCentral Syed KM, Joseph S, Mukherjee A, Majumder A, Teixeira JM, Dutta D, et al. Histone chaperone APLF regulates induction of pluripotency in murine fibroblasts. J Cell Sci. 2016;129:4576–91.PubMedPubMedCentral
2.
go back to reference Grundy GJ, Rulten SL, Zeng Z, Arribas-Bosacoma R, Iles N, Manley K, et al. APLF promotes the assembly and activity of non-homologous end joining protein complexes. EMBO J. 2013;32:112–25.CrossRefPubMed Grundy GJ, Rulten SL, Zeng Z, Arribas-Bosacoma R, Iles N, Manley K, et al. APLF promotes the assembly and activity of non-homologous end joining protein complexes. EMBO J. 2013;32:112–25.CrossRefPubMed
3.
4.
go back to reference Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast Cancer. Cell. 2015;163:506–19.CrossRefPubMedPubMedCentral Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast Cancer. Cell. 2015;163:506–19.CrossRefPubMedPubMedCentral
5.
go back to reference Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.CrossRefPubMedPubMedCentral Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.CrossRefPubMedPubMedCentral
6.
go back to reference Sarasin A, Kauffmann A. Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat Res. 2008;659:49–55.CrossRefPubMed Sarasin A, Kauffmann A. Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat Res. 2008;659:49–55.CrossRefPubMed
7.
go back to reference Timmerman LA, Grego-Bessa J, Raya A, Bertrán E, Pérez-Pomares JM, Díez J, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18:99–115.CrossRefPubMedPubMedCentral Timmerman LA, Grego-Bessa J, Raya A, Bertrán E, Pérez-Pomares JM, Díez J, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18:99–115.CrossRefPubMedPubMedCentral
8.
go back to reference Chen T, Dent SY. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat Rev Genet. 2014;15:93–106.CrossRefPubMed Chen T, Dent SY. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat Rev Genet. 2014;15:93–106.CrossRefPubMed
9.
go back to reference Gong C, Fujino K, Monteiro LJ, Gomes AR, Drost R, Davidson-Smith H, et al. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene. 2015;34:5012–24.CrossRefPubMed Gong C, Fujino K, Monteiro LJ, Gomes AR, Drost R, Davidson-Smith H, et al. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene. 2015;34:5012–24.CrossRefPubMed
10.
go back to reference Lin YC, Lee YC, Li LH, Cheng CJ, Yang RB. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci. 2014;127:85–100.CrossRefPubMed Lin YC, Lee YC, Li LH, Cheng CJ, Yang RB. Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci. 2014;127:85–100.CrossRefPubMed
Metadata
Title
Enhanced expression of histone chaperone APLF associate with breast cancer
Authors
Aditi Majumder
Khaja Moheiddin Syed
Ananda Mukherjee
Manendra Babu Lankadasari
Juberiya Mohammed Azeez
Sreeharshan Sreeja
Kuzhuvelil B. Harikumar
Madhavan Radhakrishna Pillai
Debasree Dutta
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2018
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-018-0826-9

Other articles of this Issue 1/2018

Molecular Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine